vs
Proto Labs Inc（PRLB）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
Proto Labs Inc的季度营收约是再鼎医药的1.1倍（$139.3M vs $127.1M），再鼎医药同比增速更快（17.1% vs 10.4%），过去两年再鼎医药的营收复合增速更高（20.8% vs 5.3%）
Proto Labs是一家提供快速制造服务的企业，可通过3D打印、CNC加工、钣金加工以及注塑成型工艺，为客户生产用于原型制作和量产的定制零部件，产品广泛应用于医疗设备、航空航天、电子、家电、汽车、消费品等多个领域，公司总部位于美国明尼苏达州，在美国多地设有生产基地。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
PRLB vs ZLAB — 直观对比
营收规模更大
PRLB
是对方的1.1倍
$127.1M
营收增速更快
ZLAB
高出6.7%
10.4%
两年增速更快
ZLAB
近两年复合增速
5.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $139.3M | $127.1M |
| 净利润 | $8.1M | — |
| 毛利率 | 45.6% | 51.0% |
| 营业利润率 | 7.1% | -54.6% |
| 净利率 | 5.8% | — |
| 营收同比 | 10.4% | 17.1% |
| 净利润同比 | 125.4% | — |
| 每股收益（稀释后） | $0.29 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PRLBZLAB
| Q1 26 | $139.3M | — | ||
| Q4 25 | $136.5M | $127.1M | ||
| Q3 25 | $135.4M | $115.4M | ||
| Q2 25 | $135.1M | $109.1M | ||
| Q1 25 | $126.2M | $105.7M | ||
| Q4 24 | $121.8M | $108.5M | ||
| Q3 24 | $125.6M | $101.8M | ||
| Q2 24 | $125.6M | $100.1M |
净利润PRLBZLAB
| Q1 26 | $8.1M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $7.2M | $-36.0M | ||
| Q2 25 | $4.4M | $-40.7M | ||
| Q1 25 | $3.6M | $-48.4M | ||
| Q4 24 | — | — | ||
| Q3 24 | $7.2M | $-41.7M | ||
| Q2 24 | $4.5M | $-80.3M |
毛利率PRLBZLAB
| Q1 26 | 45.6% | — | ||
| Q4 25 | 44.2% | 51.0% | ||
| Q3 25 | 45.3% | 59.5% | ||
| Q2 25 | 44.3% | 60.6% | ||
| Q1 25 | 44.1% | 63.6% | ||
| Q4 24 | 42.7% | 61.5% | ||
| Q3 24 | 45.6% | 64.1% | ||
| Q2 24 | 45.0% | 64.9% |
营业利润率PRLBZLAB
| Q1 26 | 7.1% | — | ||
| Q4 25 | 5.0% | -54.6% | ||
| Q3 25 | 6.5% | -42.3% | ||
| Q2 25 | 3.7% | -50.3% | ||
| Q1 25 | 3.6% | -53.3% | ||
| Q4 24 | -1.2% | -62.6% | ||
| Q3 24 | 6.8% | -66.6% | ||
| Q2 24 | 4.8% | -76.0% |
净利率PRLBZLAB
| Q1 26 | 5.8% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 5.3% | -31.2% | ||
| Q2 25 | 3.3% | -37.3% | ||
| Q1 25 | 2.9% | -45.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | 5.7% | -40.9% | ||
| Q2 24 | 3.6% | -80.2% |
每股收益（稀释后）PRLBZLAB
| Q1 26 | $0.29 | — | ||
| Q4 25 | $0.25 | $-0.05 | ||
| Q3 25 | $0.30 | $-0.03 | ||
| Q2 25 | $0.18 | $-0.04 | ||
| Q1 25 | $0.15 | $-0.04 | ||
| Q4 24 | $-0.01 | $-0.09 | ||
| Q3 24 | $0.29 | $-0.04 | ||
| Q2 24 | $0.18 | $-0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $124.0M | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $683.1M | $715.5M |
| 总资产 | $778.6M | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PRLBZLAB
| Q1 26 | $124.0M | — | ||
| Q4 25 | $128.1M | $689.6M | ||
| Q3 25 | $119.2M | $717.2M | ||
| Q2 25 | $103.2M | $732.2M | ||
| Q1 25 | $96.8M | $757.3M | ||
| Q4 24 | $103.1M | $779.7M | ||
| Q3 24 | $100.5M | $616.1M | ||
| Q2 24 | $112.9M | $630.0M |
股东权益PRLBZLAB
| Q1 26 | $683.1M | — | ||
| Q4 25 | $673.9M | $715.5M | ||
| Q3 25 | $664.7M | $759.9M | ||
| Q2 25 | $664.7M | $791.7M | ||
| Q1 25 | $656.8M | $810.8M | ||
| Q4 24 | $670.2M | $840.9M | ||
| Q3 24 | $680.0M | $667.7M | ||
| Q2 24 | $685.2M | $704.2M |
总资产PRLBZLAB
| Q1 26 | $778.6M | — | ||
| Q4 25 | $763.4M | $1.2B | ||
| Q3 25 | $756.9M | $1.2B | ||
| Q2 25 | $743.3M | $1.2B | ||
| Q1 25 | $737.5M | $1.2B | ||
| Q4 24 | $743.5M | $1.2B | ||
| Q3 24 | $753.8M | $985.3M | ||
| Q2 24 | $758.2M | $987.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $17.5M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | — | $-26.7M |
| 自由现金流率自由现金流/营收 | — | -21.0% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | 2.16× | — |
| 过去12个月自由现金流最近4个季度 | — | $-158.9M |
8季度趋势，按日历期对齐
经营现金流PRLBZLAB
| Q1 26 | $17.5M | — | ||
| Q4 25 | $16.5M | $-26.0M | ||
| Q3 25 | $29.1M | $-32.0M | ||
| Q2 25 | $10.6M | $-31.0M | ||
| Q1 25 | $18.4M | $-61.7M | ||
| Q4 24 | $17.3M | $-55.8M | ||
| Q3 24 | $24.8M | $-26.8M | ||
| Q2 24 | $14.4M | $-42.2M |
自由现金流PRLBZLAB
| Q1 26 | — | — | ||
| Q4 25 | $8.4M | $-26.7M | ||
| Q3 25 | $25.0M | $-35.0M | ||
| Q2 25 | $9.1M | $-33.9M | ||
| Q1 25 | $17.1M | $-63.2M | ||
| Q4 24 | $16.5M | $-58.4M | ||
| Q3 24 | $23.2M | $-28.2M | ||
| Q2 24 | $10.2M | $-42.9M |
自由现金流率PRLBZLAB
| Q1 26 | — | — | ||
| Q4 25 | 6.2% | -21.0% | ||
| Q3 25 | 18.5% | -30.4% | ||
| Q2 25 | 6.7% | -31.1% | ||
| Q1 25 | 13.6% | -59.9% | ||
| Q4 24 | 13.5% | -53.8% | ||
| Q3 24 | 18.5% | -27.7% | ||
| Q2 24 | 8.2% | -42.9% |
资本支出强度PRLBZLAB
| Q1 26 | — | — | ||
| Q4 25 | 5.9% | 0.5% | ||
| Q3 25 | 3.0% | 2.6% | ||
| Q2 25 | 1.1% | 2.6% | ||
| Q1 25 | 1.0% | 1.5% | ||
| Q4 24 | 0.7% | 2.4% | ||
| Q3 24 | 1.2% | 1.3% | ||
| Q2 24 | 3.3% | 0.7% |
现金转化率PRLBZLAB
| Q1 26 | 2.16× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 4.03× | — | ||
| Q2 25 | 2.39× | — | ||
| Q1 25 | 5.11× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.44× | — | ||
| Q2 24 | 3.18× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PRLB
| CNC Machining | $63.2M | 45% |
| Injection Molding | $51.1M | 37% |
| 3D Printing | $20.5M | 15% |
| Sheet Metal | $4.4M | 3% |
| Other Revenue | $207.0K | 0% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
